CAR T-cell constructs targeting the CD30 antigen have been tested in cHL in phase I and phase II trials revealing to be effective and safe, with low incidence of the typical CAR T-cells-related toxicities cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS) (Figure 2) [150]. Here, TNFRSF8 is linked to classic Hodgkin lymphoma.